Clinical Trial Update: A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of INO-1001, a PARP inhibitor, in acute myocardial infarction patients undergoing primary percutaneous coronary intervention; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• INO-1001 (PARP inhibitor)

Snippet

Sponsor: Inotek Pharmaceuticals Corporation | Conditions: Acute Myocardial Infarction | Phase 2 | Status: COMPLETED